Enterprise Value

8.487B

Cash

3.656B

Avg Qtr Burn

N/A

Short % of Float

4.31%

Insider Ownership

1.58%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer

Approved

Quarterly sales

Pemazyre® (pemigatinib) Details
8p11 myeloproliferative syndrome

Approved

Quarterly sales

Axatilimab Details
Graft-versus-host disease

PDUFA

Approval decision

NDA

FDA meeting

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Initiation

Phase 3

Initiation

Phase 3

Initiation

Povorcitinib (JAK1) Details
Hidradenitis suppurativa

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

Phase 1

Data readout

Failed

Discontinued